MedTrace Logo

Clinical Performance of the MaterniT21 PLUS LDT in Multiple Gestation Pregnancies

NCT02226315 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2015-09-17

No results posted yet for this study

Summary

This study will evaluate the clinical performance of massively parallel sequencing (MPS) using the MaterniT21 PLUS LDT in the detection of fetal aneuploidy in circulating cfDNA extracted from a maternal blood sample obtained from women pregnant with a multiple gestation who were at increased risk for fetal aneuploidy.

Conditions

  • Down Syndrome
  • Edwards Syndrome
  • Patau Syndrome
  • Turner Syndrome

Sponsors & Collaborators

  • Friends Research Institute, Inc.

    collaborator OTHER

  • Sequenom, Inc.

    lead INDUSTRY

Principal Investigators

  • Richard Porreco, MD · Presbyterian/St. Luke's Medical Center

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02226315 on ClinicalTrials.gov